Auriga Maintains a 'Buy' on Health Management (HMA); Q1 Beats with Higher Revenues

Auriga maintains a 'Buy' on Health Management (NYSE: HMA) price target of $12.00.

Analyst, Glen Losev, said, "HMA reported non-GAAP EPS of $0.24, in line with our and above consensus estimate of $0.22. The beat came on s-f revenue growth of +5.7% and continued margin expansion. Volumes , as expected, were soft, pressured by weak flu season and decline in uninsured admission in the quarter. More importantly, surgical volumes continued to increase and marked the tenth consecutive quarter of growth. Our rating is based on our view that HMA's deployment of the latest medical surgical systems in its facilities will continue to drive company's surgical market share. This, combined with margin expansion opportunity at the recently acquired facilities, capacity to do more transactions, and focus on costs should continue to drive earnings in 2012 and beyond, all without an improving economy."

For an analyst ratings summary and ratings history on Health Management click here. For more ratings news on Health Management click here.

Shares of Health Management closed at $7.15 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Bernstein SocGen Group Reiterates Outperform Rating on JD.com, Inc (JD), 'very cheaply valued'
• Vivos Therapeutics posts 35% revenue gain but widens net loss